Literature DB >> 8390917

Intra-arterial infusion chemotherapy on unresectable hepatocellular carcinoma under occlusion of hepatic arterial flow.

Y Une1, J Uchino, M Yasuhara, K Misawa, T Kamiyama, T Shimamura, N Sato, Y Nakajima, Y Hata.   

Abstract

Intra-arterial infusion chemotherapy (IAIC) by occluding hepatic arterial flow augments intrahepatic drug concentrations, resulting in response rates higher than those with conventional infusion methods. We recently developed an intra-hepatic artery catheter and device attached with an implantable double-lumen reservoir that can be used for repeated IAIC in outpatient clinics. Eight patients with unresectable hepatocellular carcinoma were treated by infusion of anticancer drugs using this method. The catheter was inserted into the hepatic artery under laparotomy. The occlusion balloon was attached to the common hepatic artery, and catheters were connected to the subcutaneous double-lumen reservoir. Approximately 0.5 ml of distilled water was injected through the one port of the double-lumen reservoir to inflate the balloon, which compressed the artery within the cylinder-like occluder. 4'-O-tetrahydropyranyladriamycin (THP-ADM) was used as the anticancer agent, and two patients received combined administration with carboplatin. Three to seven repeated infusions were possible without any severe side effects. This treatment was also easy to perform in the outpatient clinic. Six of the eight patients survived for more than 2 years, an improvement over the survival rates obtained in a previous conventional IAIC group. We conclude that IAIC with THP-ADM for unresectable hepatocellular carcinoma under occluding blood flow using our device is more convenient and more effective than other available methods.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8390917

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  4 in total

1.  A newly developed double lumen microballoon catheter with a side hole: initial experience of intraarterial infusion chemotherapy and/or embolization.

Authors:  Masamichi Koganemaru; Toshi Abe; Hiroshi Anai; Norimitsu Tanaka; Masaaki Nonoshita; Ryoji Iwamoto; Masashi Kusumoto; Asako Kuhara; Tomoko Kugiyama; Naofumi Hayabuchi
Journal:  Jpn J Radiol       Date:  2012-09-08       Impact factor: 2.374

2.  Efficacy of postoperative transarterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma complicated by portal vein tumor thrombosis--a randomized study.

Authors:  Q Li; J Wang; Y Sun; Y L Cui; J T Juzi; H X Li; B Y Qian; X S Hao
Journal:  World J Surg       Date:  2006-11       Impact factor: 3.352

3.  Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Yung-Chih Lai; Cheng-Yen Shih; Chin-Ming Jeng; Sien-Sing Yang; Jui-Ting Hu; Yung-Chuan Sung; Han-Ting Liu; Shaw-Min Hou; Chi-Hwa Wu; Tzen-Kwan Chen
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

4.  Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis.

Authors:  Daichi Takizawa; Satoru Kakizaki; Naondo Sohara; Ken Sato; Hitoshi Takagi; Hirotaka Arai; Kenji Katakai; Akira Kojima; Yutaka Matsuzaki; Masatomo Mori
Journal:  Dig Dis Sci       Date:  2007-03-30       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.